Tevogen Bio reports 74% insider ownership of outstanding shares

Tevogen Bio Holdings Inc. (NASDAQ: TVGN) reported that executive officers and board members collectively hold over 74% of the company's outstanding common stock, according to a July 10, 2025 Form 8-K filing with the Securities and Exchange Commission.

The Warren, New Jersey-based biotechnology company disclosed the ownership structure as part of its most recent regulatory filing. Chief Executive Officer Dr. Ryan Saadi stated that retaining majority control allows decision-making to remain with the management team.

"By retaining majority control, decision making on direction and continued rapid growth remains in the hands of our team, which is critical to our strategic philosophy as well as our aspiration to redefine the future of medicine," Saadi said in the company's statement.

Tevogen develops T cell therapeutics for infectious diseases and cancers, along with artificial intelligence applications through its Tevogen.AI platform. The company indicated it has funding for continued development of what it describes as off-the-shelf, genetically unmodified T cell treatments.

The company said it plans to share additional details about its operations in coming days. The information was disclosed in a press release statement issued by the company on July 30, 2025.

You May Also Be Interested In

• Cognizant shareholder derivative settlement gets preliminary approval
• Apnimed files for initial public offering on Nasdaq
• Mary Junck to retire from Lee Enterprises board in July